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be considered when prescription drug benefits are de-
signed.
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OBJECTIVE: The State Hospital Association (SHA) in a
large Midwestern state annually publishes risk-adjusted
mortality rates on selected groups of patients, by hospi-
tal. For the third year in a row, the SHA reported a
higher than expected mortality rate for Non-Surgical
‘Heart’ cases at Memorial, and the Board of Directors
asked for an improvement plan. METHODS: We used
the CaduCIS risk assessment methodology to indepen-
dently validate the SHA’s findings, and conducted oppor-
tunity analyses to identify a specific sub-population which
seemed to be the major contributor to the mortality rate.
RESULTS: (1) Most of the “excess” mortality seemed to
occur in medically managed AMI patients. (2) While a
few physicians cared for high volumes of such patients, a
surprising number of physicians had very low volumes.
(3) Risk-adjusted outcomes for the low-volume physi-
cians were significantly worse than predicted. (4) A non-
cardiologist was the attending physician for fully 25% of
the medically managed patients. (5) A small percentage
(4%) of medically managed AMI cases were admitted to
the Neuro ICU rather than the Cardiac ICU—but the
mortality rate in that subgroup was 58%—11% of the
total deaths. (6) Thrombolytic therapy was administered
to only 1% of medically managed AMI patients. (7) Beta-
blockers were administered to only 58% of patients. Im-
provement strategies included retargeting educational
programs, providing ongoing feedback on mortality rates,
and modifying clinical protocols. CONCLUSIONS: (1)
For the three-month time period following the implemen-
tation of improvement strategies for medically managed
AMI patients, the mortality rate decreased from 19% to
8%. (2) No AMI patients were admitted to the Neuro
ICU. (3) The proportion of AMI admissions directly
managed by cardiologists increased to 84%. (4) The fre-
quency of beta-blocker administration improved to 82%.
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OBJECTIVE: To examine the impact of demographics,
clinical/functional status, and type of medication on out-
patient utilization for persons enrolled in the US Schizo-
phrenia Care and Assessment Program (SCAP). METH-
ODS: Baseline data was used to predict 6-month
outpatient utilization (n  530). Psychotherapy (individ-
ual and group), clinic (medical services for specimen col-
lection), and total number of outpatient visits (psycho-
therapy, clinic, day treatment, rehabilitation) were examined.
Adherence at baseline and at six months reflected the 4-
week period prior to each assessment. Negative binomial
regression was used and predicted values obtained
through joint determination (SURE) of clinical/functional
status were used in the models. Standard errors were ad-
justed. RESULTS: Psychotherapy Visits: Persons using
second-generation medications exhibited more psycho-
therapy visits than their counterparts using first-genera-
tion agents and adherence at baseline only exhibited a
positive association. Clinic Visits: Non-whites exhibited
fewer visits and adherence at baseline only was associ-
ated with more visits. Total Outpatient Visits: 1) Persons
in better health exhibited more visits; 2) adherence at
baseline only was positively associated with more outpa-
tient visits; and 3) higher PANSSGP was positively associ-
ated with total visits while higher MADRS exhibited a
negative association. Season of birth and site of service
were significant in the models. CONCLUSIONS: Clinical/
functional status, medication regimen, and medication
non-adherence are significant determinants of psychiatric
service utilization. The presence of second-generation
medications, better health, and adherence to medications
is associated with greater involvement in psychotherapy,
which suggests the possibility that these factors may pro-
mote community functioning.
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Using input from consumers, clinical staff, and quality of
life experts, we developed a self-administered, health-
related quality of life instrument for individuals with
schizophrenia living in the community—the Schizophre-
nia Outcomes Assessment Project 51-item Health Status
Survey (SOAP-51). OBJECTIVE: To establish the con-
current and discriminatory validity of the SOAP-51
Health Status Survey. METHOD: We asked 1500 indi-
viduals with schizophrenia and their caregivers in 5 eth-
nically and geographically diverse states to complete the
SOAP-51; retention was 84.2%. For concurrent valida-
tion, consumers were asked to globally rate the impact of
their condition on each of SOAP-51’s 8 factors; Cron-
bach’s alpha was 0.711–0.881, test-retest reliability was
